The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
The Genomic Landscape of the Ewing Sarcoma Family of Tumors Reveals Recurrent STAG2 Mutation
Open accessAbstract
The Ewing sarcoma family of tumors (EFT) is a group of highly malignant small round blue cell tumors occurring in children and young adults. We report here the largest genomic survey to date of 101 EFT (65 tumors and 36 cell lines). Using a combination of whole genome sequencing and targeted sequencing approaches, we discover that EFT has a very low mutational burden (0.15 mutations/Mb) but frequent deleterious mutations in the cohesin complex subunit STAG2 (21.5% tumors, 44.4% cell lines), homozygous deletion of CDKN2A (13.8% and 50%) and mutations of TP53 (6.2% and 71.9%). We additionally note an increased prevalence of the BRCA2 K3326X polymorphism in EFT patient samples (7.3%) compared to population data (OR 7.1, p = 0.006). Using whole transcriptome sequencing, we find that 11% of tumors pathologically diagnosed as EFT lack a typical EWSR1 fusion oncogene and that these tumors do not have a characteristic Ewing sarcoma gene expression signature. We identify samples harboring novel fusion genes including FUS-NCATc2 and CIC-FOXO4 that may represent distinct small round blue cell tumor variants. In an independent EFT tissue microarray cohort, we show that STAG2 loss as detected by immunohistochemistry may be associated with more advanced disease (p = 0.15) and a modest decrease in overall survival (p = 0.10). These results significantly advance our understanding of the genomic and molecular underpinnings of Ewing sarcoma and provide a foundation towards further efforts to improve diagnosis, prognosis, and precision therapeutics testing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trapnell, C., Williams, B. A., Pertea, G., Mortazavi, A., Kwan, G., van Baren, M. J., Salzberg, S. L., Wold, B. J., & Pachter, L. (2010) · Nature Biotechnology · doi:10.1038/nbt.1621 · Cited by 15,556
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,621
Circos: An information aesthetic for comparative genomics
Krzywinski, M., Schein, J., Birol, İ., Connors, J., Gascoyne, R., Horsman, D., Jones, S. J., & Marra, M. A. (2009) · Genome Research · doi:10.1101/gr.092759.109 · Cited by 10,964
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456 · cited 1×
“For example, preclinical data suggest that cohesin deficiency may increase sensitivity to poly(ADP–ribose) polymerase (PARP) inhibition [55], a drug class that has also been identified by systematic screening to be effective in Ewing sarcoma cell lines [56], and that is undergoing clinical testing in this tumor type.”
BackgroundSelf-citationHuman Genome Sequencing Using Unchained Base Reads on Self-Assembling DNA Nanoarrays
Drmanac, R., Sparks, A. B., Callow, M. J., Halpern, A. L., Burns, N. L., Kermani, B. G., Carnevali, P., Nazarenko, I., Nilsen, G. B., Yeung, G., et al. (2010) · Science · doi:10.1126/science.1181498 · Cited by 1,212 · cited 1×
“0 [57], ANNOVAR v2012-05-25 [58], and Circos v0.”
Self-citationDelattre, O., Zucman, J., Melot, T., Garau, X. S., Zucker, J.-M., Lenoir, G. M., Ambros, P. F., Sheer, D., Turc-Carel, C., Triche, T. J., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199408043310503 · Cited by 1,107
Self-citationDiverse somatic mutation patterns and pathway alterations in human cancers
Kan, Z., Jaiswal, B. S., Stinson, J., Janakiraman, V., Bhatt, D., Stern, H. M., Yue, P., Haverty, P. M., Bourgon, R., Zheng, J., et al. (2010) · Nature · doi:10.1038/nature09208 · Cited by 1,027
Skálová, A., Vanecek, T., Sima, R., Laco, J., Weinreb, I., Perez-Ordonez, B., Starek, I., Geierova, M., Simpson, R. H., Passador-Santos, F., et al. (2010) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181d9efcc · Cited by 1,023
Cited by
Whole-genome landscape of pancreatic neuroendocrine tumours
Initiative, A. P. C. G., Scarpa, A., Chang, D. K., Nones, K., Corbo, V., Patch, A.-M., Bailey, P., Lawlor, R. T., Johns, A. L., Miller, D. K., et al. (2017) · Nature · doi:10.1038/nature21063 · Cited by 999
Grünewald, T. G. P., Cidre-Aranaz, F., Surdez, D., Tomazou, E. M., de Álava, E., Kovar, H., Sorensen, P. H., Delattre, O., & Dirksen, U. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0003-x · Cited by 873
The Genomic Landscape of Pediatric Ewing Sarcoma
Crompton, B. D., Stewart, C., Taylor-Weiner, A., Alexe, G., Kurek, K. C., Calicchio, M. L., Kiezun, A., Carter, S. L., Shukla, S. A., Mehta, S. S., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-1037 · Cited by 566
Tirode, F., Surdez, D., Ma, X., Parker, M., Le Deley, M. C., Bahrami, A., Zhang, Z., Lapouble, E., Grossetête-Lalami, S., Rusch, M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0622 · Cited by 565
Cancer-Specific Retargeting of BAF Complexes by a Prion-like Domain
Boulay, G., Sandoval, G. J., Riggi, N., Iyer, S., Buisson, R., Naigles, B., Awad, M. E., Rengarajan, S., Volorio, A., McBride, M. J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.036 · Cited by 470
Uncovering novel mutational signatures by de novo extraction with SigProfilerExtractor
Islam, S. M. A., Díaz-Gay, M., Wu, Y., Barnes, M., Vangara, R., Bergstrom, E. N., He, Y., Vella, M., Wang, J., Teague, J. W., et al. (2022) · Cell Genomics · doi:10.1016/j.xgen.2022.100179 · Cited by 365
Self-citationRiggi, N., Suvà, M. L., & Stamenkovic, I. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2028910 · Cited by 344
Transcriptomic definition of molecular subgroups of small round cell sarcomas
Watson, S., Perrin, V., Guillemot, D., Reynaud, S., Coindre, J., Karanian, M., Guinebretière, J., Freneaux, P., Le Loarer, F., Bouvet, M., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5053 · Cited by 335
Ewing Sarcoma—Diagnosis, Treatment, Clinical Challenges and Future Perspectives
Zöllner, S. K., Amatruda, J. F., Bauer, S., Collaud, S., de Álava, E., DuBois, S. G., Hardes, J., Hartmann, W., Kovar, H., Metzler, M., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081685 · Cited by 271
Peneder, P., Stütz, A. M., Surdez, D., Krumbholz, M., Semper, S., Chicard, M., Sheffield, N. C., Pierron, G., Lapouble, E., Tötzl, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23445-w · Cited by 200
EWS/FLI confers tumor cell synthetic lethality to CDK12 inhibition in Ewing sarcoma
Iniguez, A. B., Stolte, B., Wang, E. J., Conway, A. S., Alexe, G., Dharia, N. V., Kwiatkowski, N., Zhang, T., Abraham, B. J., Mora, J., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.12.009 · Cited by 173
“Moreover, three recent massively parallel sequencing efforts revealed that Ewing sarcoma tumors possess very low mutation rates, harboring few recurrent mutations other than EWS/ETS rearrangements (Brohl et al., 2014; Crompton et al., 2014; Tirode et al., 2014).”
Biology of Bone Sarcomas and New Therapeutic Developments
Brown, H. K., Schiavone, K., Gouin, F., Heymann, M.-F., & Heymann, D. (2018) · Calcified Tissue International · doi:10.1007/s00223-017-0372-2 · Cited by 163
Shulman, D. S., Klega, K., Imamovic-Tuco, A., Clapp, A., Nag, A., Thorner, A. R., Van Allen, E., Ha, G., Lessnick, S. L., Gorlick, R., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0212-9 · Cited by 149
Aran, V., Devalle, S., Meohas, W., Heringer, M., Cunha Caruso, A., Pinheiro Aguiar, D., Leite Duarte, M. E., & Moura Neto, V. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103340 · Cited by 87
Shukla, N. N., Patel, J. A., Magnan, H., Zehir, A., You, D., Tang, J., Meng, F., Samoila, A., Slotkin, E. K., Ambati, S. R., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00028 · Cited by 52
Shah, A. T., Azad, T. D., Breese, M. R., Chabon, J. J., Hamilton, E. G., Straessler, K., Kurtz, D. M., Leung, S. G., Spillinger, A., Liu, H.-Y., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0987 · Cited by 42
Krumbholz, M., Eiblwieser, J., Ranft, A., Zierk, J., Schmidkonz, C., Stütz, A. M., Peneder, P., Tomazou, E. M., Agaimy, A., Bäuerle, T., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1324 · Cited by 39
Maqueda, J. J., De Feo, A., & Scotlandi, K. (2024) · Biomolecules · doi:10.3390/biom14101306 · Cited by 4
Metadata
- Authors
- Brohl, A. S., Solomon, D. A., Chang, W., Wang, J., Song, Y., Sindiri, S., Patidar, R., Hurd, L., Chen, L., Shern, J. F., Liao, H., Wen, X., Gerard, J., Kim, J.-S., Lopez Guerrero, J. A., Machado, I., Wai, D. H., Picci, P., Triche, T., Horvai, A. E., Miettinen, M., Wei, J. S., Catchpool, D., Llombart-Bosch, A., Waldman, T., & Khan, J.
- Venue
- PLoS Genetics
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-07-10
- Volume
- 10
- Issue
- 7
- Pages
- e1004475
- ISSN
- 1553-7390 (ISSN-L)
- 1553-7404
- OpenAlex
- W2044351445
- Cited by
- 435
- References
- 59
- FWCI
- 27.14
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.